PE20170939A1 - Pirimidinonas como inhibidores del factor xia - Google Patents

Pirimidinonas como inhibidores del factor xia

Info

Publication number
PE20170939A1
PE20170939A1 PE2017000527A PE2017000527A PE20170939A1 PE 20170939 A1 PE20170939 A1 PE 20170939A1 PE 2017000527 A PE2017000527 A PE 2017000527A PE 2017000527 A PE2017000527 A PE 2017000527A PE 20170939 A1 PE20170939 A1 PE 20170939A1
Authority
PE
Peru
Prior art keywords
pyrimidinones
inhibitors
fxia
chloro
refers
Prior art date
Application number
PE2017000527A
Other languages
English (en)
Spanish (es)
Inventor
Andrew K Dilger
James R Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Kumar Balashanmuga Pabbisetty
William R Ewing
Yeheng Zhu
Ruth R Wexler
Donald J P Pinto
Michael J Orwat
Ii Leon M Smith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20170939A1 publication Critical patent/PE20170939A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2017000527A 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia PE20170939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01

Publications (1)

Publication Number Publication Date
PE20170939A1 true PE20170939A1 (es) 2017-07-13

Family

ID=53784023

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020001966A PE20210922A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia
PE2017000527A PE20170939A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2020001966A PE20210922A1 (es) 2014-10-01 2015-07-29 Pirimidinonas como inhibidores del factor xia

Country Status (34)

Country Link
EP (4) EP3828186B1 (https=)
JP (4) JP6462865B2 (https=)
KR (2) KR102269999B1 (https=)
CN (3) CN106795161B (https=)
AR (1) AR101367A1 (https=)
AU (3) AU2015324530B2 (https=)
CA (1) CA2963395C (https=)
CL (1) CL2017000712A1 (https=)
CO (1) CO2017003833A2 (https=)
CY (2) CY1119678T1 (https=)
DK (2) DK3089979T3 (https=)
EA (1) EA031590B1 (https=)
ES (3) ES2963267T3 (https=)
HR (2) HRP20171950T1 (https=)
HU (2) HUE052812T2 (https=)
IL (2) IL251434B (https=)
LT (2) LT3293186T (https=)
MA (1) MA40123A1 (https=)
MX (2) MX376056B (https=)
MY (2) MY201397A (https=)
NO (1) NO2721243T3 (https=)
PE (2) PE20210922A1 (https=)
PH (2) PH12017500580B1 (https=)
PL (1) PL3089979T3 (https=)
PT (2) PT3293186T (https=)
RS (2) RS56786B1 (https=)
SG (2) SG11201702576QA (https=)
SI (2) SI3293186T1 (https=)
SM (2) SMT202000667T1 (https=)
TN (2) TN2017000112A1 (https=)
TW (3) TWI834182B (https=)
UY (1) UY36244A (https=)
WO (1) WO2016053455A1 (https=)
ZA (1) ZA201702478B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (https=) 2014-01-31 2018-03-10
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
CN107001391B (zh) 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (https=) * 2014-10-01 2018-10-20
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
ES2762987T3 (es) 2015-06-19 2020-05-26 Bristol Myers Squibb Co Macrociclos de diamida como inhibidores del factor XIA
JP6629958B2 (ja) * 2015-07-29 2020-01-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキルまたはシクロアルキルＰ２’基を担持する大員環の第ＸＩａ因子阻害剤
CN114874222B (zh) 2015-07-29 2025-06-06 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
BR112018068676A2 (pt) 2016-03-31 2019-01-15 Janssen Pharmaceuticals Inc derivados de indol substituídos como inibidores da replicação viral do dengue
BR112018069601A2 (pt) 2016-03-31 2019-01-29 Janssen Pharmaceuticals Inc derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110062757B (zh) * 2017-01-18 2022-03-04 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3630723B1 (en) 2017-05-22 2022-08-24 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
BR112021020257A2 (pt) * 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico
BR112021020368A2 (pt) * 2019-04-11 2021-12-07 Bristol Myers Squibb Co Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona
WO2020211781A1 (zh) * 2019-04-16 2020-10-22 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CN114008047B (zh) * 2019-07-23 2023-03-21 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
MX2022003649A (es) * 2019-09-27 2022-06-08 Shenzhen Salubris Pharm Co Ltd Inhibidores del fxia y metodo de preparacion de los mismos y uso farmaceutico de los mismos.
IL297206A (en) * 2020-04-10 2022-12-01 Bristol Myers Squibb Co Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1-yl)phenyl] -6-oxo- 1,6-dihydropyrimidine - 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02 6] octadeca- 1(18), 2(6), 4, 14, 16- pentaene -8-one
AU2021317436A1 (en) * 2020-07-29 2023-02-23 Shanghai Curegene Pharmaceutical Co., Ltd. Antiplatelet drugs and uses thereof
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
JP2024505390A (ja) * 2021-01-08 2024-02-06 ブリストル－マイヤーズ スクイブ カンパニー 第ｘｉａ因子阻害剤としての抗体および抗原結合ペプチド、およびその使用
CN117603208A (zh) * 2021-04-21 2024-02-27 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途
KR20260032556A (ko) * 2023-06-30 2026-03-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 다치환된 거대환식 화합물 및 이의 제조 방법과 용도
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
NZ602266A (en) * 2010-02-11 2014-05-30 Bristol Myers Squibb Co Macrocycles as factor xia inhibitors
US9327839B2 (en) * 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
US9732085B2 (en) * 2011-12-21 2017-08-15 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor Xia
US9376444B2 (en) * 2012-08-03 2016-06-28 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
AU2013296259A1 (en) * 2012-08-03 2015-03-19 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (https=) * 2014-01-31 2018-03-10
NO2721243T3 (https=) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
KR20170057431A (ko) 2017-05-24
CA2963395C (en) 2023-03-14
PT3293186T (pt) 2020-12-09
JP2017530157A (ja) 2017-10-12
EP3828186A2 (en) 2021-06-02
PL3089979T3 (pl) 2018-02-28
KR101921436B1 (ko) 2018-11-22
TN2017000112A1 (en) 2018-07-04
TW202043228A (zh) 2020-12-01
MX2017003695A (es) 2017-05-30
EP3828186A3 (en) 2021-07-28
TWI692478B (zh) 2020-05-01
RS61183B1 (sr) 2021-01-29
JP2021185182A (ja) 2021-12-09
JP6937734B2 (ja) 2021-09-22
CN106795161B (zh) 2019-10-15
CN114957255A (zh) 2022-08-30
EA031590B1 (ru) 2019-01-31
MY201397A (en) 2024-02-21
HRP20171950T1 (hr) 2018-02-23
KR102269999B1 (ko) 2021-06-25
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (en) 2016-11-09
SMT202000667T1 (it) 2021-01-05
NO2721243T3 (https=) 2018-10-20
PT3089979T (pt) 2018-01-16
CN110734435A (zh) 2020-01-31
MA40123A1 (fr) 2017-09-29
JP6462865B2 (ja) 2019-01-30
TW202310844A (zh) 2023-03-16
SMT201800021T1 (it) 2018-03-08
SI3089979T1 (sl) 2017-12-29
IL276470B (en) 2021-04-29
DK3293186T3 (da) 2020-12-14
EP3293186B1 (en) 2020-09-23
JP2019069989A (ja) 2019-05-09
ZA201702478B (en) 2019-06-26
IL251434B (en) 2020-08-31
TN2018000229A1 (en) 2019-10-04
TWI834182B (zh) 2024-03-01
UY36244A (es) 2016-01-29
SG10201911652TA (en) 2020-02-27
CA2963395A1 (en) 2016-04-07
HUE038061T2 (hu) 2018-09-28
PH12017500580B1 (en) 2020-10-09
DK3089979T3 (en) 2018-01-15
CL2017000712A1 (es) 2017-11-03
TWI769442B (zh) 2022-07-01
EP4286372A2 (en) 2023-12-06
AU2021245098A1 (en) 2021-10-28
AU2021245098B2 (en) 2023-11-23
EA201790595A1 (ru) 2017-07-31
JP2023134734A (ja) 2023-09-27
AU2020200376B2 (en) 2021-07-08
IL251434A0 (en) 2017-05-29
ES2836270T3 (es) 2021-06-24
LT3293186T (lt) 2020-12-28
AU2020200376A1 (en) 2020-02-06
EP4286372A3 (en) 2024-02-21
IL276470A (en) 2020-09-30
CN110734435B (zh) 2022-06-07
PH12020500195A1 (en) 2021-02-08
NZ731416A (en) 2024-01-26
JP7317905B2 (ja) 2023-07-31
CN106795161A (zh) 2017-05-31
PH12017500580A1 (en) 2017-08-30
BR112017006702A2 (pt) 2017-12-26
CY1119678T1 (el) 2018-04-04
HUE052812T2 (hu) 2021-05-28
KR20180126612A (ko) 2018-11-27
MX376056B (es) 2025-03-07
ES2655884T3 (es) 2018-02-22
NZ766570A (en) 2024-01-26
HRP20201927T1 (hr) 2021-02-05
EP3089979B1 (en) 2017-10-18
LT3089979T (lt) 2017-12-27
RS56786B1 (sr) 2018-04-30
TW201613923A (en) 2016-04-16
MX2020010840A (es) 2020-11-06
ES2963267T3 (es) 2024-03-26
SG11201702576QA (en) 2017-04-27
CY1123663T1 (el) 2022-03-24
PE20210922A1 (es) 2021-05-19
WO2016053455A1 (en) 2016-04-07
AR101367A1 (es) 2016-12-14
EP3828186B1 (en) 2023-08-23
MY183987A (en) 2021-03-17
SI3293186T1 (sl) 2021-01-29
AU2015324530B2 (en) 2019-10-24
EP3293186A1 (en) 2018-03-14
AU2015324530A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
PE20170939A1 (es) Pirimidinonas como inhibidores del factor xia
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CY1120534T1 (el) Μακροκυκλικοι αναστολεις παραγοντα χια συμπυκνωμενοι με ετεροκυκλους
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
EA201691471A1 (ru) Макроциклы с гетероциклическими группами p2' как ингибиторы фактора xia
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
PH12016501388A1 (en) Heteroaryls and uses thereof
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
TW201613872A (en) IRAK4 inhibiting agents
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
EA201691302A1 (ru) Новые гетероциклические соединения
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
BR112017028577A2 (pt) forma cristalina de um maleato do derivado de piridina fundida e usos da mesma
PH12017500595A1 (en) Aldosterone synthase inhibitors
EA202191885A3 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4